Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Aug 2;73(3):531-534.
doi: 10.1093/cid/ciaa1176.

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A Ivashchenko  1 , Kirill A Dmitriev  2 , Natalia V Vostokova  3 , Valeria N Azarova  3 , Andrew A Blinow  4 , Alina N Egorova  3 , Ivan G Gordeev  5 , Alexey P Ilin  6 , Ruben N Karapetian  7 , Dmitry V Kravchenko  6 , Nikita V Lomakin  8 , Elena A Merkulova  3 , Natalia A Papazova  9 , Elena P Pavlikova  10 , Nikolay P Savchuk  11 , Elena N Simakina  12 , Tagir A Sitdekov  2 , Elena A Smolyarchuk  13 , Elena G Tikhomolova  14 , Elena V Yakubova  4 , Alexandre V Ivachtchenko  11
Affiliations
Clinical Trial

AVIFAVIR for Treatment of Patients With Moderate Coronavirus Disease 2019 (COVID-19): Interim Results of a Phase II/III Multicenter Randomized Clinical Trial

Andrey A Ivashchenko et al. Clin Infect Dis. .

Abstract

In May 2020 the Russian Ministry of Health granted fast-track marketing authorization to RNA polymerase inhibitor AVIFAVIR (favipiravir) for the treatment of COVID-19 patients. In the pilot stage of Phase II/III clinical trial, AVIFAVIR enabled SARS-CoV-2 viral clearance in 62.5% of patients within 4 days, and was safe and well-tolerated. Clinical Trials Registration. NCT04434248.

Keywords: AVIFAVIR; COVID-19; SARS-CoV-2; favipiravir.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
A, Elimination of SARS-CoV-2 in nasopharyngeal and/or oropharyngeal swabs of patients treated with AVIFAVIR or SOC on Day 5 and Day 10 of the study treatment. B, Time to normal body temperature in patients treated with AVIFAVIR or SOC (Kaplan-Meier curves). Abbreviations: SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; SOC, standard of care.
See this image and copyright information in PMC

Comment in

  • In the Fog of Coronavirus Disease (COVID).
    Zaia JA. Zaia JA. Clin Infect Dis. 2022 Feb 11;74(3):511-512. doi: 10.1093/cid/ciaa1292. Clin Infect Dis. 2022. PMID: 32857845 Free PMC article. No abstract available.
  • Reply to Krishna Prabha et al.
    Ivashchenko AA, Savchuk NP, Yakubova EV, Ivachtchenko AV. Ivashchenko AA, et al. Clin Infect Dis. 2021 Aug 2;73(3):e848-e849. doi: 10.1093/cid/ciaa1606. Clin Infect Dis. 2021. PMID: 33099607 No abstract available.

References

    1. Sisay M. Available evidence and ongoing clinical trials of remdesivir: could it be a promising therapeutic option for COVID-19? Front Pharmacol 2020; 11:791. - PMC - PubMed
    1. Avigan Tablet 200 mg. Report on the Deliberation Results. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau. Ministry of Health, Labour and Welfare. March 4, 2014, Pharmaceuticals and Medical Devices Agency, January 23, 2014. Available at: https://www.pmda.go.jp/files/000210319.pdf.
    1. Wang M, Cao R, Zhang L, et al. . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30:269–71. - PMC - PubMed
    1. Cai Q, Yang M, Liu D, et al. . Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering 2020. Journal Pre-proofs. doi:10.1016/j.eng.2020.03.007 - DOI - PMC - PubMed
    1. WHO R&D Blueprint COVID 19 Experimental Treatments. COVID Classification of treatment types. 2020. Available at: https://www.who.int/docs/default-source/coronaviruse/covid-classificatio....

Publication types

Substances

Associated data